Astral Systems

What Astral Systems does

Astral Systems (legal entity: Astral Neutronics Ltd) is a Bristol, UK-based fusion technology company founded in May 2021 that has developed a proprietary Multi-State Fusion (MSF) platform producing compact fusion reactors and neutron services. The company's product line spans the Mk01 (1e8 n/s DD), Mk1 MSF Reactor (1e9 n/s DD / 1e11 n/s DT), and Mk2 MSF Reactor (1e10 n/s DD / 1e12 n/s DT), all claimed to deliver 10x greater neutron output and 25,000+ hours operating lifetime versus current market alternatives. These reactors power three revenue streams: hardware sales (Mk0/Mk1/Mk2 reactor units), neutron irradiation services for research, materials testing, and industrial applications, and planned decentralized production of medical radioisotopes including Cu-64, Cu-67, Ac-225, Pb-212, Tb-161, and I-131 for cancer diagnosis and treatment, targeting market entry by 2027.

The company goes to market through an enterprise field sales motion with a consultative process across a horizontally segmented customer base spanning healthcare providers and medical isotope distributors, research institutions and national laboratories, and industrial/aerospace/energy buyers requiring materials testing and radiation hardness validation. Distribution is direct, with the Mk2 reactor restricted to strategic partner arrangements. Go-to-market is supported by technical credibility channels including CTO-authored content in the Nuclear Industry Association's Industry Link magazine, participation in industry events such as the Tritium User Group, and a network of research and government partnerships with UKAEA, National Nuclear Laboratory, NPL, UKRI STFC, and multiple UK and international universities.

Astral Systems has raised over £28 million to date across a February 2025 seed round (Speedinvest and Playfair Capital co-led) and a June 2026 £23M Series A first close led by Mercia Ventures. The company currently employs 23 people at its Bristol headquarters with plans to expand to over 40 by end of 2026 and to establish a new high-energy fusion facility at the former Berkeley Power Station in Gloucestershire. Disclosed annual revenue exceeds £3 million.

Name

Astral Systems

Legal name

Astral Neutronics Ltd

Website

https://astralsystems.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Astral Systems is a Bristol-based fusion technology company that builds compact Multi-State Fusion (MSF) reactors and provides neutron irradiation services and planned decentralized medical radioisotope production, serving healthcare providers, research institutions, and industrial customers across the UK and globally.

Ownership category

akta.pro rank

Product category

Fusion Reactor Technology

NAICS

Irradiation Apparatus Manufacturing (334517), Analytical Laboratory Instrument Manufacturing (334516)

SIC

X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844), Industrial Instruments For Measurement, Display, And Control (3823)

akta.pro primary industry

Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA)

akta.pro secondary industries

Industrial Isotope Production & Supply (Co-60, Ir-192, Cs-137, Am-241, etc.) (EUAKAIAB), Gen IV / Advanced Reactor Systems (SFR, LFR, GFR, MSR, HTGR, Microreactors) (EUAKADAC), Nuclear Materials Testing, Assay & Characterization Services (NDA/NDE, radiochemistry, materials analysis) (EUAKAIAL)

Keywords

• Compact fusion reactors
• Medical isotope production
• Neutron irradiation services
• Radiopharmaceutical supply
• Nuclear research hardware

Headquarters

HQ city

Bristol

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Infrastructure, Marketing or Sales

Revenue model

1. MSF Reactor Sales: Sale of multi-state fusion (MSF) reactors - Mk0, Mk1, and Mk2 models with varying neutron output capacities for research, industrial, and medical applications.
2. Neutron Irradiation Services: Provides neutron irradiation testing services including research, teaching and training, spent fission fuel assay, neutronics research, industrial neutron irradiations, accelerated lifetime testing (ALT), isotope production, and fission and fusion fuel-cycle testing.
3. Medical Isotope Production: Production and sale of medical radioisotopes including Cu-64, Cu-67, Ac-225, Pb-212, Tb-161, and I-131 for cancer diagnosis and treatment. Targets market entry by 2027.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Astral Systems designs, manufactures, and sells compact multi-state fusion (MSF) reactors (Mk01, Mk1, Mk2 models) that produce high-energy neutrons for medical isotope production, research applications, and industrial irradiations. The reactors are complemented by neutron irradiation services and an isotope-agnostic production platform enabling decentralized manufacturing of medical radioisotopes such as Cu-64, Cu-67, Ac-225, Pb-212, Tb-161, and I-131 for cancer diagnosis and treatment. The technology targets customers in healthcare, nuclear research, and industrial sectors requiring compact, high-output neutron sources.

Product overview

Astral Systems offers a modular Multi-State Fusion (MSF) reactor product line (Mk01, Mk1, Mk2) providing 10x greater neutron output and 10x longer lifetime than market alternatives. The reactors operate with operating lifetimes exceeding 25,000 hours across all models. The company complements its hardware with neutron testing services enabling high-energy fusion volumetric neutron irradiation for research, materials testing, and calibration. Medical isotope production services leverage the neutron capability to produce radioisotopes (Cu-64, Cu-67, Ac-225, Pb-212, Tb-161, I-131) for cancer diagnosis and treatment.

Differentiator

Problem solved

Functional benefit

Products and services

• Mk01 MSF Reactor Entry-level multi-state fusion reactor producing 1e8 neutrons per second in deuterium-deuterium (DD) mode. Available for purchase for research, industrial, and medical isotope production applications.
• Mk1 MSF Reactor Multi-state fusion reactor producing 10x greater neutron output than current market alternatives, with 1e9 n/s (DD) and 1e11 n/s (DT) capability and 25,000+ hour operating lifetime. Available for purchase.
• Mk2 MSF Reactor Advanced multi-state fusion reactor with 1e10 n/s (DD) and 1e12 n/s (DT) output capacity. Available only to strategic partners due to its higher capacity and specialized commercial arrangements.
• Neutron Testing Services High-energy fusion volumetric neutron source services for research, neutron irradiation, radiation hardness testing, accelerated lifetime testing (ALT), spent fission fuel assay, neutronics research, materials damage testing, tritium research, and calibration. Provides detailed energy spectra for 2.45 MeV and 14 MeV neutrons.
• Medical Isotope Production Decentralized production of medical radioisotopes including Cu-64, Cu-67, Ac-225, Pb-212, Tb-161, and I-131 using fusion-based neutron production for cancer diagnosis and treatment. Targets commercial market entry by 2027.

Quantifiable outcome

• 10x greater neutron output compared to current market alternatives
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eleven partnerships are on record, tiered research partner, core partner, incubator/accelerator and government partner.

• Bangor Universityresearch partnerStrategic or Co-development PartnerAcademic partner collaborating on fusion and nuclear research initiatives.
• Kyoto University (Institute for Integrated Radiation and Nuclear Science)research partnerStrategic or Co-development PartnerJapanese university research partner in nuclear science and radiation research.
• National Nuclear Laboratorycore partnerStrategic or Co-development PartnerUK's primary nuclear laboratory providing expertise and facilities for nuclear research and development.
• National Physical Laboratoryresearch partnerStrategic or Co-development PartnerUK's national measurement institute for precision measurement and standards.
• Purdue Universityresearch partnerStrategic or Co-development PartnerUS university partner in nuclear engineering and physics research.
• SETsquared Bristolincubator/acceleratorStrategic or Co-development PartnerBristol-based technology business incubator supporting high-growth companies.
• Technische Universität Dresdenresearch partnerStrategic or Co-development PartnerGerman technical university partner in fusion and nuclear research.
• UK Atomic Energy Authoritycore partnerStrategic or Co-development PartnerUK government organisation responsible for the development of fusion power, a key strategic partner for fusion technology development.
• UKRI Science and Technology Facilities Councilresearch partnerStrategic or Co-development PartnerUK research council providing funding and facilities for science and technology research.
• University of Bristolresearch partnerStrategic or Co-development PartnerHome university and research partner in Bristol, collaborating on fusion technology development.
• Welsh Governmentgovernment partnerStrategic or Co-development PartnerWelsh Government providing support and collaboration for regional technology development.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• SHINE Technologies: SHINE Technologies is a US-based fusion company producing medical isotopes (Mo-99, I-131, Lu-177) using a fusion-driven neutron source. It is the most directly comparable peer to Astral, competing in the same fusion-based medical isotope production market with a similar technical approach.
• Phoenix (formerly Phoenix Nuclear Labs): Phoenix produces high-yield neutron generators using accelerator-based fusion for industrial neutron testing, radiography, and isotope production. It overlaps with Astral's neutron testing services and shares the 'compact fusion for neutrons' core thesis.

Emerging players

• NorthStar Medical Radioisotopes: NorthStar produces Mo-99 and other medical isotopes using electron accelerator technology rather than fission. It targets the same domestic isotope supply gap as Astral with a different technical approach and is further along commercially.
• TAE Technologies: TAE Technologies is a well-capitalized fusion energy company pursuing a different fusion approach (field-reversed configuration). While primarily focused on energy, its fusion platform and neutron-related applications overlap with Astral's broader technology space.
• Helion Energy: Helion is a US fusion energy company developing pulsed fusion for electricity generation. It is less directly comparable on isotopes but operates in the same compact-fusion deep-tech category and competes for similar deep-tech capital and talent.
• Telix Pharmaceuticals: Telix is a rapidly growing radiopharmaceutical company developing diagnostic and therapeutic products. It represents the downstream demand for Astral's isotope production and is a potential off-take partner.

Broad incumbents

• Curium Pharma: Curium is one of the world's largest nuclear medicine companies, producing a broad portfolio of diagnostic and therapeutic radioisotopes. It is the established incumbent whose aging supply chain Astral aims to disrupt.
• IBA (Ion Beam Applications): IBA is a global leader in cyclotron-based isotope production and proton therapy. Its cyclotrons are widely used for PET isotope production, making it a competing approach to Astral's fusion-based neutron source for medical isotope manufacturing.
• Lantheus Holdings: Lantheus is a leading radiopharmaceutical company focused on diagnostic imaging agents. It is a key downstream buyer of medical isotopes that Astral would supply, and a benchmark for the commercial economics of the isotope supply chain.
• Commonwealth Fusion Systems: Commonwealth Fusion Systems is a leading commercial fusion company pursuing high-temperature superconducting tokamaks. Although focused on energy rather than neutrons, it is the largest private fusion competitor for capital, talent, and regulatory attention.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/astralsystems

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds2 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Astral Systems